GHRP-2 vs GHRP-6

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicGHRP-2GHRP-6
What it is

A synthetic hexapeptide amide (D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2), also recorded as pralmorelin and KP-102, according to FDA’s substance registry.2

A synthetic hexapeptide amide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), also recorded as hexapeptide-2 and SK&F-110679, according to FDA’s substance registry.3

FDA status

Not FDA-approved

No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1

No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, and its 503A nominations list, updated May 14, 2026, places it in category 3.1,4

Is GHRP-2 FDA-approved?

Not FDA-approved

No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1

No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-6 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.1

Is GHRP-6 FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.5,6

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not among them.5,6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.1

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-6 in category 2 under the interim policy for outsourcing facilities (section 503B) since September 29, 2023, citing possible immune reactions from aggregation and impurities.1

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial A double-blind, randomized, placebo-controlled study in 19 healthy lean and obese adults, each tested on three visits, published in 2006.7
  • Small, short, or incompletely reported human study A 2007 Japanese diagnostic study in 77 healthy people and 58 patients with severe growth hormone deficiency, measuring the growth hormone response to GHRP-2.8
  • Small, short, or incompletely reported human study Reports, cited by FDA, of serious adverse events in patients who received GHRP-2, including higher insulin needs, deaths of critically ill study participants, infection and pancreatitis, with causality not established.1

Limited human data

  • Small, short, or incompletely reported human study A 2013 pharmacokinetic study in nine healthy men, which measured how quickly GHRP-6 is distributed and cleared, without a comparison group.9
Records collected

0 ClinicalTrials.gov records and 21 PubMed records collected

0 ClinicalTrials.gov records and 25 PubMed records collected

Area of study

Hormones2

Hormones3

Latest dated events
  1. FDA’s 503A nominations list, as last updated, places GHRP-2 in category 3.4
  2. FDA’s compounding safety-risk page, as last updated, keeps GHRP-2 in category 2.1
  3. FDA places GHRP-2 in category 2 under its 503B interim compounding policy, according to its safety-risk page.1
  1. FDA’s compounding safety-risk page, as last updated, keeps GHRP-6 in category 2.1
  2. FDA places GHRP-6 in category 2 under its 503B interim compounding policy, according to its safety-risk page.1
  3. A pharmacokinetic study of GHRP-6 in nine healthy men is published.9

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Pralmorelin (GHRP-2) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  3. 3
    GHRP-6 (hexapeptide-2) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake (2006) · PMID 16861611 ↗

    Obesity · Official source · Source checked November 16, 2026

  8. 8
    A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007) · PMID 17609397 ↗

    European Journal of Endocrinology · Official source · Source checked November 16, 2026

  9. 9
    Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers (2013) · PMID 23099431 ↗

    European Journal of Pharmaceutical Sciences · Official source · Source checked November 15, 2026